Certain dosage strengths of Wegovy (semaglutide) will be in short supply through September 2023, according to Novo Nordisk.
Wegovy is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) in the presence of at least 1 weight-related comorbid condition (eg, hypertension, type 2 diabetes mellitus, or dyslipidemia); and in pediatric patients aged 12 years and older with an initial BMI at the 95th percentile or greater for age and sex (obesity).
Wegovy is supplied in a prefilled, single-dose pen in 5 dosage strengths: 0.25 mg/0.5 mL, 0.5 mg/0.5 mL, 1 mg/0.5 mL, 1.7 mg/0.75 mL, and 2.4 mg/0.75 mL. Novo Nordisk noted that while the capacity of production has increased, the supply of the 0.25 mg, 0.5 mg, and 1 mg dosage strengths will likely be limited through September. With regard to the 1.7 mg and 2.4 mg, the Company does not anticipate supply interruptions for these dosage strengths.
Continue Reading
In a letter to health care providers, the Company recommended that “health care providers take into consideration the limited supply of the 0.25 mg, 0.5 mg, and 1 mg dose strengths of Wegovy as part of their decision-making when initiating new patients on therapy, recognizing the possibility of disruption in care.”
Reference
Product Supply Information. Novo Nordisk. Accessed May 5, 2023. https://www.novomedlink.com/obesity/products/treatments/wegovy/resources/product-supply-information.html.
This article originally appeared on MPR
